FIELD: biotechnology.
SUBSTANCE: invention relates to recombinant IL-5-binding molecules, and can be used in medicine in the production of drugs targeting IL-5 for the treatment of leukemia. The following is proposed: an IL-5-binding molecule capable of specifically binding to interleukin-5 (IL-5) and containing a single immunoglobulin variable domain with a defined set of complementarity determining regions CDR1, CDR2 and CDR3.
EFFECT: invention makes it possible to obtain a molecule capable of specifically binding to IL-5 and effectively blocking cell proliferation induced by IL-5.
14 cl, 8 dwg, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-IL-17A ANTIBODY AND USE THEREOF | 2019 |
|
RU2816204C2 |
| HUMANIZED SINGLE-DOMAIN ANTIBODY TO IL-4Rα AND ITS USE | 2021 |
|
RU2816867C1 |
| GIPR ANTIBODY AND ITS GLP-1 FUNCTION PROTEIN AS WELL AS PHARMACEUTICAL COMPOSITION BASED ON IT AND ITS USE | 2019 |
|
RU2800370C2 |
| ANTIBODY AGAINST IL-5, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2772716C2 |
| TREATMENT AND INHIBITION OF INFLAMMATORY LUNG DISEASES IN PATIENTS WITH RISK ALLELES IN GENES ENCODING IL33 AND IL1RL1 | 2018 |
|
RU2776241C2 |
| ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
| ANTIBODIES CONTAINING POLYPEPTIDE INTEGRATED INTO FRAME REGION 3 | 2019 |
|
RU2796254C2 |
| ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
| MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE | 2021 |
|
RU2808563C2 |
| ANTIBODY FOR SPECIFIC BINDING WITH INTERLEUKIN 4 RECEPTOR | 2017 |
|
RU2774446C2 |
